Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety and Tolerability of Human TH-SC01 Cell Injection for the Treatment of Perianal Fistulas in Crohn's Disease

NCT05626023 is registered in ClinicalTrials.gov with Jiangsu Topcel-KH Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05626023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05626023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety and Tolerability of Human TH-SC01 Cell Injection for the Treatment of Perianal Fistulas in Crohn's Disease
Lead sponsor
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
January 30, 2022
Completion date
February 28, 2025
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, perianal fistula